Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96PB1

UPID:
CASD1_HUMAN

ALTERNATIVE NAMES:
CAS1 domain-containing protein 1; Sialate O-acetyltransferase

ALTERNATIVE UPACC:
Q96PB1; B3KW13; O14574; Q3LIE2; Q6P4R4; Q9H6T9; Q9H770

BACKGROUND:
The enzyme N-acetylneuraminate 9-O-acetyltransferase, known for its alternative name Sialate O-acetyltransferase, is integral in the post-translational modification of sialic acids. These modifications are essential for processes like cell-cell communication and the recognition mechanisms between host and pathogens.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of N-acetylneuraminate 9-O-acetyltransferase unveils potential pathways for therapeutic intervention. Given its critical role in modulating sialic acids, which are key in immune responses and pathogen interactions, this protein presents a promising avenue for the development of novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.